CN107793351B - 一种β-氨基酸的合成方法及采用该方法合成的β-氨基酸 - Google Patents

一种β-氨基酸的合成方法及采用该方法合成的β-氨基酸 Download PDF

Info

Publication number
CN107793351B
CN107793351B CN201610802406.0A CN201610802406A CN107793351B CN 107793351 B CN107793351 B CN 107793351B CN 201610802406 A CN201610802406 A CN 201610802406A CN 107793351 B CN107793351 B CN 107793351B
Authority
CN
China
Prior art keywords
beta
amino acid
intermediate compound
compound
synthesized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610802406.0A
Other languages
English (en)
Other versions
CN107793351A (zh
Inventor
张书宇
白贺元
丁同梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jiaotong University
Original Assignee
Shanghai Jiaotong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jiaotong University filed Critical Shanghai Jiaotong University
Priority to CN201610802406.0A priority Critical patent/CN107793351B/zh
Publication of CN107793351A publication Critical patent/CN107793351A/zh
Application granted granted Critical
Publication of CN107793351B publication Critical patent/CN107793351B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/40Nitrogen atoms attached in position 8
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明涉及一种新的β‑氨基酸的合成方法及采用该方法合成的β‑氨基酸,所述的方法是以酰胺、偶氮二酸酯为原料,在催化剂作用下,通过直接碳‑氢键胺基化合成中间化合物I,后与溴乙酸甲酯反应合成中间化合物II,于酸性条件下脱除酰胺保护基团,即合成得到β‑氨基酸;合成制得的β‑氨基酸的化学结构式为:
Figure DDA0001109635240000011
式中:R1、R2选自氢、烷基、支链烷基、环烷基、芳香基、带各种取代基的芳香基、杂环基或带各种取代基的杂环基;R3为酯基。与现有技术相比,本发明方法通过直接碳‑氢键胺基化的过程合成中间化合物I,可以大范围拓展底物,合成的α、β位有取代基的β‑氨基酸具有结构多样性,为α、β位有取代基的β‑氨基酸的工业化生产提供了一种新方法。

Description

一种β-氨基酸的合成方法及采用该方法合成的β-氨基酸
技术领域
本发明属于有机化学合成技术领域,涉及一种新的β-氨基酸的合成方法及采用该方法合成的β-氨基酸。
背景技术
近年来,在自然界中存在较少的β-氨基酸受到越来越广泛的关注。β-氨基酸是大量具有β-内酰胺结构的抗生素的合成前体,而某些β-氨基酸本身就具有生物活性,如(S)-2-苯基-3-氨基丙酸是青霉素β-优卡因(Betacine)的侧链,而其乙酯衍生物又具有神经活性。β-氨基酸存在于一些天然的生物活性肽链中,例如,(2S,3R)-2-羟基-3-氨基-4-苯基丁酸存在于著名的免疫响应调节剂Bestatin中。结构功能化的β-氨基酸是许多生物活性分子的重要组成部分。著名的抗癌药紫杉醇(Taxol)的13位侧链为α-羟基-β-氨基酸,该侧链对于紫杉醇的药理活性是必要的。
CN1435408A中介绍了一种α位有取代基的β-氨基酸的一步加氢合成法,以氰基乙酸乙酯和醛为原料,产率最高为69.7%。CN1511826A中介绍了以酮为原料合成β-氨基酸的方法,采用的方法为丙二酸法、氰基乙酸乙酯法或氰基乙酸法,产率约为70%。CN101525299A中介绍了将醛、丙二酸和苄胺通过一锅法合成N-苄基β-氨基酸,再在钯碳催化剂作用下转化为游离β-氨基酸,产率约为76%。但这些方法合成的β-氨基酸并没有α、β位同时被取代,得到的β-氨基酸缺乏结构多样性。
发明内容
本发明的目的就是为了克服上述现有技术存在的缺陷而提供一种反应条件温和,可重复性好,可用于工业化生产的β-氨基酸的合成新方法及采用该方法合成的β-氨基酸。
本发明的目的可以通过以下技术方案来实现:
一种β-氨基酸的合成方法,该方法是以酰胺、偶氮二酸酯为原料,在催化剂作用下,通过直接碳-氢键胺基化合成中间化合物I,后与溴乙酸甲酯反应合成中间化合物II,于酸性条件下脱除酰胺保护基团,即合成得到β-氨基酸;
所述的酰胺的化学结构式为:
Figure BDA0001109635230000021
式中:R1、R2选自氢、烷基、支链烷基、环烷基、芳香基、带各种取代基的芳香基、杂环基或带各种取代基的杂环基,R4为酰胺保护基团;
所述的偶氮酸酯的化学结构式为:R3-N=N-R3,式中:R3为酯基;
所述的中间化合物I的化学结构式为:;
Figure BDA0001109635230000022
所述的中间化合物II的化学结构式为:
Figure BDA0001109635230000023
所述的酰胺保护基团R4包括8-氨基喹啉或1-(2-吡啶基)-1-甲基乙胺中的一种,所述的酯基R3包括甲酸烷基酯或甲酸芳香酯的一种。
一种β-氨基酸的合成方法具体包括以下步骤:
(a)将酰胺与偶氮羧酸酯在催化剂、溶剂A的作用下,氧气保护,发生直接碳-氢键胺基化反应,合成中间化合物I;
(b)将步骤(a)合成的中间化合物I与溴乙酸甲酯反应,在碳酸铯、溶剂B的作用下,于40~80℃搅拌0.5~2.5h,经萃取、提纯、干燥,制得中间产物,进一步在碳酸铯、溶剂B的作用下,于50~100℃反应,经萃取、提纯、干燥,合成中间化合物II;
(c)将步骤(b)合成的中间化合物II加入盐酸中,于100~200℃反应20~60h,即制得所述的β-氨基酸。
本发明方法的合成工艺路线为:
Figure BDA0001109635230000031
步骤(a)中所述的催化剂包括醋酸钯、特戊酸钯或三苯基膦醋酸钯中的一种或多种;所述的溶剂A包括2-甲基-2-丁醇、甲苯、二氯乙烷、二氯甲烷、氯苯、乙腈、四氢呋喃、1,4-二氧六环、丙酮、正己烷、环己烷、二甲基甲酰胺或二甲基亚砜中的一种或多种。
步骤(a)中所述的催化剂与酰胺的摩尔比为1-20:100,优选5-15:100。
步骤(a)中所述的酰胺与偶氮酸酯的摩尔比为1:1-10,优选1:1-5。
步骤(a)中胺基化反应的温度为50-150℃,反应时间为8-48h,优选20-30h。
步骤(b)中所述的溶剂B为乙腈。
采用上述方法制备而成的β‐氨基酸,化学结构式为:
Figure BDA0001109635230000032
式中:R1、R2选自氢、烷基、支链烷基、环烷基、芳香基、带各种取代基的芳香基、杂环基或带各种取代基的杂环基;R3为酯基。
与现有技术相比,本发明方法通过直接碳-氢键胺基化的过程合成化合物(I),化合物(I)与溴乙酸甲酯反应得到化合物(II),进一步在酸作用下脱酰胺保护基团后得到β-氨基酸。本发明合成方法所选底物的取代基具有多样,从而决定了合成的α、β位有取代基的β-氨基酸的结构多样性,所用工艺条件比较温和,为α、β位有取代基的β-氨基酸的工业化生产提供了一条新思路。
具体实施方式
下面结合具体实施例对本发明进行详细说明。
本实施方式中,化合物的氢核磁共振谱(1H NMR)由Bruker AVANCE III HD400测定;质谱(ESI-MS)由SolariX-70FT-MS测定;所用试剂均为市售试剂。
实施例1:3-((乙氧羰基)氨基)丁酸的制备
将0.2mmol N-(2-(吡啶-2-基)丙烷-2-基)丁酰胺、0.02mmol Pd(OAc)2、0.4mmol偶氮二甲酸二乙酯、1mL 2-甲基-2-丁醇加入反应瓶中,氧气吹扫,密封后加热至110℃反应24h,冷却到室温后,减压蒸馏、提纯后得到化合物(I),收率为83%。
后将0.1mmol化合物(I)、0.2mmol溴乙酸甲酯溶于乙腈后,加入0.25mmol碳酸铯,50℃反应1h。经萃取、洗涤、减压蒸馏得到悬浮液后加入碳酸铯,乙腈作溶剂,回流反应后,经过萃取、减压蒸馏得到无色晶体化合物(II),收率为81%。
再将0.05mmol化合物(II)加入盐酸140℃反应48h,冷却后减压蒸馏,经水洗、干燥、减压蒸馏得到3-((乙氧羰基)氨基)丁酸。
化合物(I)为:
Figure BDA0001109635230000041
1H NMR(CDCl3,400MHz,ppm):δ8.49(br,1H),7.91-7.48(m,2H),7.35(d,J=8.0Hz,1H),7.15-7.12(m,1H),4.64(br,1H),4.23-4.07(m,4H),2.37-2.15(m,2H),1.67(s,3H),1.63(s,3H),1.30-1.09(m,9H);13C NMR(CDCl3,100MHz,ppm)δ169.9,164.4,155.8,147.9,137.0,121.7,119.4,61.8,56.6,52.5,42.1,27.7,18.6,14.5,14.4;HRMS:calculated forC18H29N4O5[M+H+]:381.2132;found:381.2131.
化合物(II)为:
Figure BDA0001109635230000042
1H NMR(CDCl3,400MHz,ppm):δ8.47-8.46(m,1H),7.72(s,1H),7.70-7.65(m,1H),7.36(d,J=8.0Hz,1H),7.17-7.14(m,1H),5.90(s,1H),4.08-3.98(m,3H),2.48-2.29(m,2H),1.72(s,3H),1.69(s,3H),1.22-1.16(m,6H);13C NMR(CDCl3,100MHz,ppm)δ170.1,164.2,156.0,147.6,137.0,121.8,119.3,60.4,56.7,44.6,42.9,27.7,27.3,20.2,14.6;HRMS:calculated for C15H24N3O3[M+H+]:294.1812;found:294.1810.
实施例2:3-((乙氧羰基)氨基)苯丙酸的制备
将0.2mmol 3-苯基-N-(2-(吡啶-2-基)丙烷-2-基)丙酰胺、0.02mmol Pd(OAc)2、0.6mmol偶氮二甲酸二乙酯、1mL 2-甲基-2-丁醇加入反应瓶中,氧气吹扫,密封后加热至100℃反应24h,冷却到室温后,减压蒸馏去除溶剂,提纯后得到化合物(I),收率为87%。
后将0.1mmol化合物(I)、0.2mmol溴乙酸甲酯溶于乙腈后,加入0.25mmol碳酸铯,50℃反应1h。经萃取、洗涤、减压蒸馏得到悬浮液后加入碳酸铯,乙腈作溶剂,回流反应后,经过萃取、减压蒸馏得到无色晶体化合物(II),收率为80%。
再将0.05mmol化合物(II)加入盐酸140℃反应48h,冷却后减压蒸馏,经水洗、干燥、减压蒸馏得到3-((乙氧羰基)氨基)苯丙酸。
化合物(I)为:
Figure BDA0001109635230000051
1H NMR(CDCl3,400MHz,ppm):δ8.51-8.50(d,J=4Hz,1H),7.88-7.35(m,2H),7.37-7.22(m,6H),7.14-7.13(m,1H),5.70(br,1H),4.30-4.04(m,4H),3.02(br,1H),2.66(d,J=10.4Hz,1H),1.69(s,3H),1.63(s,3H),1.32-1.21(m,6H);13C NMR(CDCl3,100MHz,ppm)δ169.4,164.5,155.9,147.9,138.8,136.8,128.4,127.8,127.5,121.6,119.4,62.7,62.1,59.3,56.9,39.9,27.7,14.4.HRMS:calculated for C23H31N4O5[M+H+]:443.2289;found:443.2287.
实施例3:3-((乙氧羰基)氨基)-4-甲基戊酸的制备
将0.2mmol 4-甲基-N-(2-(吡啶-2-基)丙烷-2-基)戊酰胺、0.04mmol Pd(OAc)2、0.4mmol偶氮二甲酸二乙酯、1mL二氯乙烷加入反应瓶中,氧气吹扫,密封后加热至110℃反应24h,冷却到室温后,减压蒸馏去除溶剂,提纯后得到化合物(I),收率为66%。
将0.1mmol化合物(I)、0.2mmol溴乙酸甲酯溶于乙腈后,加入0.25mmol碳酸铯,60℃反应2h。经萃取、洗涤、减压蒸馏得到悬浮液后加入碳酸铯,乙腈作溶剂,回流反应后,经过萃取、减压蒸馏得到无色晶体化合物(II),收率为85%。
再将0.05mmol化合物(II)加入盐酸140℃反应48h,冷却后减压蒸馏,经水洗、干燥、减压蒸馏得到得到3-((乙氧羰基)氨基)-4-甲基戊酸。
化合物(I)为:
Figure BDA0001109635230000061
1H NMR(CDCl3,400MHz,ppm):δ8.52(d,J=9.6Hz,1H),7.87-7.52(m,2H),7.36(d,J=8.0Hz,1H),7.16-7.13(m,1H),4.20-4.03(m,5H),2.48-2.41(m,2H),2.21-1.85(m,1H),1.77(s,3H),1.69(s,3H),1.31-1.17(m,6H),1.07-1.00(m,3H),0.93(d,J=6.4Hz,3H);13CNMR(CDCl3,100MHz,ppm)δ170.7,164.3,156.6,147.8,137.0,121.7,119.4,62.2,62.0,56.7,38.2,31.3,27.6,20.1,19.4,14.4;HRMS:calculated for C20H33N4O5[M+H+]:409.2445;found:409.2444.
实施例4:3-((乙氧羰基)氨基)己二酸的制备
将0.2mmol甲基-6-氧-6-((2-(吡啶-2-基)丙烷-2-基)氨基)己酸酯、0.04mmol Pd(OAc)2、0.3mmol偶氮二甲酸二乙酯、1mL甲苯加入反应瓶中,氧气吹扫,密封后加热至120℃反应36h,冷却到室温后,减压蒸馏去除溶剂,提纯后得到化合物(I),收率为72%。
将0.1mmol化合物(I)、0.2mmol溴乙酸甲酯溶于乙腈后,加入0.25mmol碳酸铯,80℃反应2h。经萃取、洗涤、减压蒸馏得到悬浮液后加入碳酸铯,乙腈作溶剂,回流反应后,经过萃取、减压蒸馏得到无色晶体化合物(II),收率为76%。
再将0.05mmol化合物(II)加入盐酸140℃反应48h,冷却后减压蒸馏,经水洗、干燥、减压蒸馏得到得到3-((乙氧羰基)氨基)己二酸。
化合物(I)为:
Figure BDA0001109635230000062
1H NMR(CDCl3,400MHz,ppm):δ8.50(d,J=8.8Hz,1H),7.83-7.47(m,2H),7.34(d,J=8.0Hz,1H),7.14(br,1H),4.59-4.51(m,1H),4.20-4.17(m,4H),3.62(s,3H),2.71-2.16(m,4H),1.79-1.50(m,8H),1.30-1.17(m,6H);13C NMR(CDCl3,100MHz,ppm)δ174.3,169.7,164.1,157.9,156.0,147.8,137.0,121.7,119.4,62.3,56.7,54.8,51.5,41.2,40.7,30.8,27.6,14.4;HRMS:calculated for C21H33N4O7[M+H+]:453.2344;found:453.2341.
实施例5-7为以不同取代基酰胺为原料合成化合物(I)。
实施例5:
将0.2mmol 2-甲基-N-(2-(吡啶-2-基)丙烷-2-基)丁酰胺、0.04mmol Pd(OAc)2、0.5mmol偶氮二甲酸二乙酯、1mL 2-甲基-2-丁醇加入反应瓶中,氧气吹扫,密封后加热至100℃反应18h,冷却到室温后,减压蒸馏去除溶剂,提纯后得到化合物(I),收率为43%。
化合物(I)为:
Figure BDA0001109635230000071
1H NMR(CDCl3,400MHz,ppm):δ8.55-8.52(m,1H),8.35-8.24(m,0.6H),7.68(t,J=8Hz,1H),7.36-7.34(m,1.4H),7.23-7.15(m,1H),4.38-4.07(m,5H),2.44(br,1H),1.72(s,3H),1.62(s,3H),1.28-1.26(m,6H),1.21-1.16(m,6H);13C NMR(CDCl3,100MHz,ppm)δ173.7,164.6,155.6,148.1,137.2,121.8,119.3,61.7,57.8,56.4,46.0,28.2,27.0,16.3,15.1,14.4;HRMS:calculated for C19H31N4O5[M+H+]:395.2289;found:395.2287.
实施例6:
将0.2mmol 2-苯基-N-(喹啉-8-基)丁酰胺、0.04mmol Pd(OAc)2、0.4mmol偶氮二甲酸二乙酯、1mL 2-甲基-2-丁醇加入反应瓶中,氧气吹扫,密封后加热至120℃反应48h,冷却到室温后,减压蒸馏去除溶剂,提纯后得到化合物(I),收率为36%。
化合物(I)为:
Figure BDA0001109635230000072
1H NMR(CDCl3,400MHz,ppm):δ9.82(br,1H),8.72(br,1H),8.56(br,1H),8.07(d,J=8Hz,1H),7.56-7.54(m,2H),7.44-7.35(m,5H),7.33-7.27(m,1H),5.18-4.52(m,1H),4.30-3.84(m,5H),1.37-1.25(m,3H),1.21-0.98(m,6H);13C NMR(CDCl3,100MHz,ppm)δ170.6,155.9,148.3,138.7,136.5,136.3,133.9,129.1,128.7,127.9,127.8,127.1,122.1,121.6,117.5,62.6,62.0,58.5,16.5,14.5,14.3;HRMS:calculated forC25H29N4O5[M+H+]:465.2132;found:465.2128.
实施例7:
将0.2mmol N-(2-(吡啶-2-基)丙烷-2-基)环丁基甲酰胺、0.03mmol Pd(OAc)2、0.4mmol偶氮二甲酸二乙酯、0.5mL 2-甲基-2-丁醇和0.5mL甲苯加入反应瓶中,氧气吹扫,密封后加热至110℃反应24h,冷却到室温后,减压蒸馏去除溶剂,提纯后得到化合物(I),收率为45%。
化合物(I)为:
Figure BDA0001109635230000081
1H NMR(CDCl3,400MHz,ppm):δ9.68-8.81(m,1H),8.71-8.47(m,1H),7.71-7.66(m,1H),7.34(t,J=8.0Hz,1H),7.18-7.15(m,1H),6.86-6.10(m,1H),4.98-4.84(m,1H),4.19-4.13(m,4H),3.27-3.26(m,1H),2.44-1.77(m,4H),1.72(s,3H),1.57-1.45(m,3H),1.30-1.17(m,6H),;13C NMR(CDCl3,100MHz,ppm)δ170.3,164.0,163.7,156.9,156.7,156.5,148.6,148.3,137.2,121.9,121.8,119.2,119.0,62.4,62.0,61.6,61.4,56.2,53.8,53.5,45.3,30.4,30.1,26.2,24.0,17.1,16.9,14.6,14.5,14.4;HRMS:calculated forC19H29N4O5[M+H+]:393.2132;found:393.2131.
实施例8-10为以不同偶氮酸酯为原料合成化合物(I)。
实施例8:
将0.2mmol N-(2-(吡啶-2-基)丙烷-2-基)丁酰胺、0.02mmol Pd(OAc)2、0.4mmol偶氮二甲酸二异丙酯、1mL 2-甲基-2-丁醇加入反应瓶中,氧气吹扫,密封后加热至110℃反应24h,冷却到室温后,减压蒸馏去除溶剂,提纯后得到化合物(I),收率为81%。
化合物(I)为:
Figure BDA0001109635230000091
1H NMR(CDCl3,400MHz,ppm):δ8.49(br,1H),7.78-7.48(m,2H),7.35(d,J=8.0Hz,1H),7.13(br,1H),4.95-4.84(m,2H),4.63(br,1H),2.37(br,2H),1.66(s,3H),1.64(s,3H),1.25-1.16(m,15H);13C NMR(CDCl3,100MHz,ppm)δ169.9,164.5,156.9,155.3,147.8,137.0,121.7,119.4,69.5,56.6,51.0,42.2,27.6,22.1,22.0,18.6;HRMS:calculated forC20H33N4O5[M+H+]:409.2445;found:409.2444.
实施例9:
将0.2mmol N-(2-(吡啶-2-基)丙烷-2-基)丁酰胺、0.02mmol Pd(OAc)2、0.4mmol偶氮二甲酸二叔丁酯、1mL 2-甲基-2-丁醇加入反应瓶中,氧气吹扫,密封后加热至110℃反应24h,冷却到室温后,减压蒸馏去除溶剂,提纯后得到化合物(I),收率为19%。
化合物(I)为:
Figure BDA0001109635230000092
1H NMR(CDCl3,400MHz,ppm):δ8.54-8.50(m,1H),7.66(br,1H),7.58-7.38(m,2H),7.14(br,1H),4.65(br,1H),2.56-2.34(m,1H),2.10(br,1H),1.72-1.63(m,6H),1.46(s,9H),1.40(s,9H),1.80(d,J=6.8Hz,3H);13C NMR(CDCl3,100MHz,ppm)δ170.1,164.5,156.5,154.7,147.8,137.2,121.8,119.4,80.8,56.5,50.4,42.3,28.2,27.6,18.5;HRMS:calculated for C22H37N4O5[M+H+]:437.2758;found:437.2755.
实施例10:
将0.2mmol N-(2-(吡啶-2-基)丙烷-2-基)丁酰胺、0.02mmol Pd(OAc)2、0.4mmol偶氮二甲酸二苄酯、1mL 2-甲基-2-丁醇加入反应瓶中,氧气吹扫,密封后加热至110℃反应24h,冷却到室温后,减压蒸馏去除溶剂,提纯后得到化合物(I),收率为59%。
化合物(I)为:
Figure BDA0001109635230000101
1H NMR(CDCl3,400MHz,pppm):δ8.44(br,1H),8.25-7.62(m,2H),7.35-7.26(m,11H),7.12-7.06(m,1H),5.18-5.01(m,4H),4.70(br,1H),2.39-2.12(m,2H),1.67(s,3H),1.60(s,3H),1.28-1.11(m,3H);13C NMR(CDCl3,100MHz,ppm)δ169.7,164.3,155.5,147.9,137.1,136.0,135.9,128.5,128.4,128.2,128.0,127.9,127.7,121.7,119.3,67.5,56.6,51.4,42.0,27.8,27.2,18.4;HRMS:calculated for C28H33N4O5[M+H+]:505.2445;found:505.2441.
上述的对实施例的描述是为便于该技术领域的普通技术人员能理解和使用发明。熟悉本领域技术的人员显然可以容易地对这些实施例做出各种修改,并把在此说明的一般原理应用到其他实施例中而不必经过创造性的劳动。因此,本发明不限于上述实施例,本领域技术人员根据本发明的揭示,不脱离本发明范畴所做出的改进和修改都应该在本发明的保护范围之内。

Claims (2)

1.一种β-氨基酸的合成方法,其特征在于,该方法具体包括以下步骤:
(a)将酰胺与偶氮二酸酯在催化剂、溶剂A的作用下,氧气保护,发生直接碳-氢键胺基化反应,合成中间化合物I;
(b)将步骤(a)合成的中间化合物I与溴乙酸甲酯反应,在碳酸铯、溶剂B的作用下,于40~80℃搅拌0.5~2.5h,经萃取、提纯、干燥,制得中间产物,进一步在碳酸铯、溶剂B的作用下,于50~100℃反应,经萃取、提纯、干燥,合成中间化合物II;
(c)将步骤(b)合成的中间化合物II加入盐酸中,于100~200℃反应20~60h,即制得所述的β-氨基酸;
步骤(a)中所述的催化剂为醋酸钯;所述的溶剂A为2-甲基-2-丁醇、甲苯或二氯乙烷;所述的催化剂与酰胺的摩尔比为1-20:100;所述的酰胺与偶氮酸酯的摩尔比为1:1-10;胺基化反应的温度为50-150℃,反应时间为8-48h;
步骤(b)中所述的溶剂B为乙腈;
所述的酰胺的化学结构式为:
Figure FDA0002593503800000011
式中:R1为氢,R2为烷基或芳香基,R4为8-喹啉基或2-(2-吡啶基)-丙基;
所述的偶氮二酸酯的化学结构式为:R3-N=N-R3,式中:R3为甲酸烷基酯;
所述的中间化合物I的化学结构式为:
Figure FDA0002593503800000012
所述的中间化合物II的化学结构式为:
Figure FDA0002593503800000013
所述β-氨基酸的化学结构式为:
Figure FDA0002593503800000014
2.根据权利要求1所述的一种β-氨基酸的合成方法,其特征在于,该方法的合成工艺路线为:
Figure FDA0002593503800000021
CN201610802406.0A 2016-09-05 2016-09-05 一种β-氨基酸的合成方法及采用该方法合成的β-氨基酸 Active CN107793351B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610802406.0A CN107793351B (zh) 2016-09-05 2016-09-05 一种β-氨基酸的合成方法及采用该方法合成的β-氨基酸

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610802406.0A CN107793351B (zh) 2016-09-05 2016-09-05 一种β-氨基酸的合成方法及采用该方法合成的β-氨基酸

Publications (2)

Publication Number Publication Date
CN107793351A CN107793351A (zh) 2018-03-13
CN107793351B true CN107793351B (zh) 2020-11-10

Family

ID=61529840

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610802406.0A Active CN107793351B (zh) 2016-09-05 2016-09-05 一种β-氨基酸的合成方法及采用该方法合成的β-氨基酸

Country Status (1)

Country Link
CN (1) CN107793351B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111635335B (zh) * 2020-06-24 2021-07-13 上海交通大学 一种手性γ-氨基酸的合成方法及采用该方法合成的手性γ-氨基酸
CN112679426B (zh) * 2020-12-30 2022-09-30 上海交通大学 用于含氮杂环合成的中间化合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101525299A (zh) * 2008-03-05 2009-09-09 爱斯特(成都)医药技术有限公司 一种合成β-氨基酸的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101525299A (zh) * 2008-03-05 2009-09-09 爱斯特(成都)医药技术有限公司 一种合成β-氨基酸的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
1558460-28-8等;Registry;《STN》;20140228;第1-6页 *
An Atom-Economic Synthesis of Nitrogen Heterocycles from Alkynes;Barry M. Trost et al.,;《J. Am. Chem. Soc.》;20101022;第133卷;第740-743页 *
Synthesis of Carbamates from Diethoxycarbonyl Hydrazine Derivatives by E1cB Eliminative Cleavage of the N-N′-Bond Rather than Reduction;Philip Magnus et al.,;《Org. Lett.》;20091112;第11卷(第24期);第5646-5648页 *

Also Published As

Publication number Publication date
CN107793351A (zh) 2018-03-13

Similar Documents

Publication Publication Date Title
AU2014310569A1 (en) Synthesis of biphenylalaninol via novel intermediates
CN110590635A (zh) 左乙拉西坦及其中间体的制备方法
CN107793351B (zh) 一种β-氨基酸的合成方法及采用该方法合成的β-氨基酸
JPS6236028B2 (zh)
CN109096122B (zh) 制备亚精胺的方法
KR20100116644A (ko) 콤브레타스타틴의 제조 방법
CN108148044B (zh) 酰胺类化合物及该化合物制备富马酸沃诺拉赞的方法
CN109320441B (zh) 一种高效制备炔酰胺类化合物的方法
CN107868033B (zh) 一种苯丙氨酸类化合物的制备方法
JP6781030B2 (ja) L−カルノシン誘導体またはその塩、及びl−カルノシンまたはその塩の製造方法
CN107663170B (zh) 制备贝西沙星中间体化合物的方法
CN107245039A (zh) 一种制备n‑羟乙基丙烯酰胺的方法
WO2014188783A1 (ja) 軸不斉を有するN-(2-アシルアリール)-2-[5,7-ジヒドロ-6H-ジベンゾ[c,e]アゼピン-6-イル]アセトアミド化合物とアミノ酸からなるキラル金属錯体を使用する光学活性α-アミノ酸の合成方法
CN111051289A (zh) 被保护的l-肌肽衍生物、l-肌肽以及结晶性l-肌肽锌络合物的制造方法
CN111116420B (zh) 一种对称脲类化合物的制备方法
CN104761420B (zh) 一种在水相中用甲基芳烃和胺合成酰胺的方法
US9790170B2 (en) Method for preparing lacosamide
JPS5826849A (ja) メタクリル−及びアクリルアミドの製造法
EP1318142B1 (en) T-butoxycarbonylaminoethylamine for the synthesis of pna monomer units, amino acid derivatives, intermediates thereof, and processes for productions of them
AU2004268983A1 (en) Cycloalkylaminoacid compounds, processes for making and uses thereof
CN112272665A (zh) 制备立他司特的方法
US6946542B2 (en) Amino amides, peptides and peptidomimetics
KR101890979B1 (ko) 알카인을 이용한 아마이드 화합물의 제조방법 및 이를 이용한 펩타이드 제조 방법
JP6277470B2 (ja) trans−1,2−ジアミノシクロヘキサンの製造方法
RU2761167C1 (ru) Способ получения картолина-2

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant